Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Min Hwan Kim

Showing results (111-120 of 119) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 119 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2025
Proliferation of tumor-related regulatory T cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancerSeung Hyuck Jeon, Koung Jin Suh, Sungmin Jung, et al.
Therapeutic Advances in Medical Oncology|November 7, 2022
Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study GroupHye Sook Han, Kyoung Eun Lee, Young Ju Suh, et al.
Breast (Edinburgh, Scotland)|August 27, 2022
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort StudyYvette Drew, Jae-Weon Kim, Richard T Penson, et al.
Therapeutic Advances in Medical Oncology|January 30, 2024
A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)Sun Kyung Baek, Jae-Ho Jeong, KyungHae Jung, et al.
Breast (Edinburgh, Scotland)|May 18, 2025
Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (-) metastatic breast cancer patients in Korea (KCSG BR21-15)Jieun Lee, Dae-Won Lee, Min Hwan Kim, et al.
Nature Communications|April 10, 2023
Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNAMingyun Bae, Gyuhee Kim, Tae-Rim Lee, et al.
BMC Cancer|August 10, 2025
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)Jieun Lee, Hee Kyung Ahn, Kyung-Hun Lee, et al.
Clinical & Translational Immunology|January 10, 2022
SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer modelsChun-Bong Synn, Sung Eun Kim, Hee Kyu Lee, et al.
Pageof 12

Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2025
Proliferation of tumor-related regulatory T cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancerSeung Hyuck Jeon, Koung Jin Suh, Sungmin Jung, et al.
Therapeutic Advances in Medical Oncology|November 7, 2022
Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study GroupHye Sook Han, Kyoung Eun Lee, Young Ju Suh, et al.
Breast (Edinburgh, Scotland)|August 27, 2022
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort StudyYvette Drew, Jae-Weon Kim, Richard T Penson, et al.
Therapeutic Advances in Medical Oncology|January 30, 2024
A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)Sun Kyung Baek, Jae-Ho Jeong, KyungHae Jung, et al.
Breast (Edinburgh, Scotland)|May 18, 2025
Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (-) metastatic breast cancer patients in Korea (KCSG BR21-15)Jieun Lee, Dae-Won Lee, Min Hwan Kim, et al.
Nature Communications|April 10, 2023
Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNAMingyun Bae, Gyuhee Kim, Tae-Rim Lee, et al.
BMC Cancer|August 10, 2025
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)Jieun Lee, Hee Kyung Ahn, Kyung-Hun Lee, et al.
Clinical & Translational Immunology|January 10, 2022
SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer modelsChun-Bong Synn, Sung Eun Kim, Hee Kyu Lee, et al.
Pageof 12